Presentation is loading. Please wait.

Presentation is loading. Please wait.

chemotherapy for patients with MC versus those with AC

Published byΙόλη Καρράς Modified over 6 years ago

Similar presentations

Presentation on theme: "chemotherapy for patients with MC versus those with AC"— Presentation transcript:

1 chemotherapy for patients with MC versus those with AC
Figure 1 Forrest plot depicting outcomes from studies of palliative and adjuvant chemotherapy for patients with MC versus those with AC Figure 1 | Forrest plot depicting outcomes from studies of palliative and adjuvant chemotherapy for patients with MC versus those with AC. Differences between categorical outcomes were calculated by the author based on primary data reported in the relevant manuscript using the risk ratio and corresponding 95% CI. Abbreviations: AC, adenocarcinoma not otherwise specified; CI, confidence interval; MC, mucinous carcinoma. Hugen, N. et al. (2015) Advances in the care of patients with mucinous colorectal cancer Nat. Rev. Clin. Oncol. doi: /nrclinonc

Download ppt "chemotherapy for patients with MC versus those with AC"

Similar presentations

Figure #1 Overall survival Figure #2 Disease free survival

Figure #1 Overall survival Figure #2 Disease free survival
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Figure 2 Underreporting by physicians of specific treatment-associated symptoms by physicians in the TORCH trial Figure 2 | Underreporting by physicians.

Figure 2 Underreporting by physicians of specific treatment-associated symptoms by physicians in the TORCH trial Figure 2 | Underreporting by physicians.
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Nat. Rev. Urol. doi: /nrurol

Nat. Rev. Urol. doi: /nrurol
Figure 4 Example of PK/PD simulation to optimize a vinorelbine treatment regimen Figure 4 | Example of PK/PD simulation to optimize a vinorelbine treatment.

Figure 4 Example of PK/PD simulation to optimize a vinorelbine treatment regimen Figure 4 | Example of PK/PD simulation to optimize a vinorelbine treatment.
Figure 5 Schematic illustration of different clinical trial designs

Figure 5 Schematic illustration of different clinical trial designs
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Figure 4 Management of personal care needs

Figure 4 Management of personal care needs
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Figure 3 Monitoring clonal evolution using liquid biopsies

Figure 3 Monitoring clonal evolution using liquid biopsies
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Figure 2 Copy-number variations in multiple myeloma

Figure 2 Copy-number variations in multiple myeloma
Figure 5 Identification of mucinous carcinoma

Figure 5 Identification of mucinous carcinoma
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Figure 1 Underreporting of treatment-related toxicities by physicians, relative to patients with either advanced-stage lung cancer, or early-stage breast.

Figure 1 Underreporting of treatment-related toxicities by physicians, relative to patients with either advanced-stage lung cancer, or early-stage breast.
Evidence Behind the 4-Hour Rule for Initiation of Antibiotic Therapy in Community- Acquired Pneumonia  Kenneth T. Yu, MD, MBA, Peter C. Wyer, MD  Annals.

Evidence Behind the 4-Hour Rule for Initiation of Antibiotic Therapy in Community- Acquired Pneumonia  Kenneth T. Yu, MD, MBA, Peter C. Wyer, MD  Annals.
Figure 2 Therapeutic targeting of the PI3K/AKT/mTOR pathway

Figure 2 Therapeutic targeting of the PI3K/AKT/mTOR pathway

Similar presentations

Ads by Google